

FGFR2

Research Grade Bemarituzumab

Catalog No.	DHD47901A DHD47901B	Quantity:	100 µg 1.0 mg
Alternate Names:	FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0		
Description:	Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell-mediated cytotoxicity.		
UniProt ID (target):	P21802		
Target:	Human Fibroblast growth factor receptor 2 (K-sam, CD332)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human IgG1 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Bemarituzumab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

